De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

PharmaCyte Biotech Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor PharmaCyte Biotech te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	28.7%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Mar 22

PharmaCyte Biotech says CEO to step down, announces strategic review of business

Oct 07

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Aug 15

Is This A Good Time To Invest In PharmaCyte?

Jan 07

PharmaCyte Biotech: Buy The 'Dump'

Aug 21

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat PharmaCyte Biotech onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NasdaqCM:PMCB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
7/31/2024	N/A	4	-3	-3	N/A
4/30/2024	N/A	-17	-2	-2	N/A
1/31/2024	N/A	-15	-2	-2	N/A
10/31/2023	N/A	-10	-2	-2	N/A
7/31/2023	N/A	-10	-2	-2	N/A
4/30/2023	N/A	-4	-4	-4	N/A
1/31/2023	N/A	-6	-5	-5	N/A
10/31/2022	N/A	-6	-4	-4	N/A
7/31/2022	N/A	-5	-4	-4	N/A
4/30/2022	N/A	-4	-4	-4	N/A
1/31/2022	N/A	-4	-4	-4	N/A
10/31/2021	N/A	-4	-4	-4	N/A
7/31/2021	N/A	-4	-4	-4	N/A
4/30/2021	N/A	-4	-3	-3	N/A
1/31/2021	N/A	-3	-3	-3	N/A
10/31/2020	N/A	-3	-3	-3	N/A
7/31/2020	N/A	-4	-2	-2	N/A
4/30/2020	N/A	-4	-2	-2	N/A
1/31/2020	N/A	-4	-2	-2	N/A
10/31/2019	N/A	-4	-3	-3	N/A
7/31/2019	N/A	-4	-3	-3	N/A
4/30/2019	N/A	-4	-3	-3	N/A
1/31/2019	N/A	-4	-4	-4	N/A
10/31/2018	N/A	-6	-4	-4	N/A
7/31/2018	N/A	-6	-5	-5	N/A
4/30/2018	N/A	-7	N/A	-5	N/A
1/31/2018	N/A	-7	N/A	-5	N/A
10/31/2017	N/A	-6	N/A	-4	N/A
7/31/2017	N/A	-5	N/A	-3	N/A
4/30/2017	N/A	-4	N/A	-3	N/A
1/31/2017	N/A	-4	N/A	-4	N/A
10/31/2016	N/A	-5	N/A	-4	N/A
7/31/2016	N/A	-6	N/A	-4	N/A
4/30/2016	N/A	-6	N/A	-4	N/A
1/31/2016	N/A	-8	N/A	-4	N/A
10/31/2015	N/A	-7	N/A	-4	N/A
7/31/2015	N/A	-10	N/A	-5	N/A
4/30/2015	N/A	-10	N/A	-5	N/A
1/31/2015	N/A	-24	N/A	-4	N/A
10/31/2014	N/A	-23	N/A	-4	N/A
7/31/2014	N/A	-24	N/A	-2	N/A
4/30/2014	N/A	-27	N/A	-2	N/A
1/31/2014	N/A	-11	N/A	-1	N/A
10/31/2013	0	-11	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van PMCB boven de spaarquote ( 2.5% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van PMCB naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van PMCB naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van PMCB naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van PMCB naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PMCB naar verwachting over 3 jaar hoog zal zijn

PharmaCyte Biotech Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

PharmaCyte Biotech, Inc. announced delayed annual 10-K filing

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for 7,750,000 shares, for $25.19 million.

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

PharmaCyte Biotech, Inc. Announces Management Changes

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech, Inc. Announces Board Appointments

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Iroquois Capital Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech

PharmaCyte Biotech, Inc. Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech, Inc. Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Iroquois Capital Commences Consent Solicitation to Reconstitute Pharmacyte Biotech Board of Directors

Iroquois Capital Issues a Statement in Response to Pharmacyte Biotech

Iroquois Capital Delivers Open Letter to Pharmacyte Biotech Board of Directors

PharmaCyte Biotech, Inc., Annual General Meeting, Aug 25, 2022

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Initiates Studies to Confirm its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. Appoints Matthias Löhr to the Board

PharmaCyte Biotech Receives A Notification Letter from Regulation Department of the Nasdaq Stock Market

PharmaCyte Biotech, Inc. Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech, Inc Updates Status of Investigational New Drug Application to FDA

Is This A Good Time To Invest In PharmaCyte?

Pharmacyte Biotech, Inc. Study Proves Capsule Material Is Not Toxic for Encapsulated Cells

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech, Inc. Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech, Inc. Announces Encapsulation Material Does Not Alter Cellular DNA

Pharmacyte Biotech, Inc. Releases More Positive Results from U.S. Food and Drug Administration-Required Biocompatibility Tests

Pharmacyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

PharmaCyte Biotech: Buy The 'Dump'

PharmaCyte Biotech Common Stock Deleted from Other OTC

PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

PharmaCyte Biotech, Inc. Announces Update on Study Progress

PharmaCyte Biotech, Inc. Announces Stability Test Results on Cells from Master Cell Bank

PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold

PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for Its Clinical Trial Product

PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for Its Clinical Trial Product

PharmaCyte Biotech, Inc. Successfully Completes 9-Month Stability Study

PharmaCyte Biotech, Inc. Receives U.S. FDA Clinical Hold Letter

PharmaCyte Biotech, Inc. Announces Dr. Gerald W. Crabtree Will No Longer Serve as Chief Operating Officer But Instead Will Serve as Chief Scientific Officer

U.S. FDA Places PharmaCyte Biotech, Inc.’s Investigational New Drug Application on Hold

PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

PharmaCyte Biotech, Inc. Successfully Completes Six-Month Stability Study

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven